Experimental antibody drug tested for Tough-to-Treat leukemia
NCT ID NCT03698552
First seen Nov 03, 2025 · Last updated Jun 10, 2026 · Updated 32 times
Summary
This study tested a drug called ADCT-602 in 37 people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that had returned or stopped responding to other treatments. The drug is a lab-made antibody that targets a protein (CD22) on cancer cells to stop them from growing. The study was stopped early, but it aimed to find the safest dose and see if the drug could shrink or eliminate the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Comprehensive Cancer
Monrovia, California, 91016, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.